GLP-1 Receptor Agonists Explained: Mechanism, Medication List, and Patient Questions

How GLP-1 receptor agonists work (plain-language mechanism)

GLP-1 receptor agonists mimic the incretin pathway that normally activates after eating. In practice, they help support glucose control by increasing glucose-dependent insulin secretion and reducing glucagon activity. They also slow gastric emptying and can increase satiety, which is part of why some of these agents are used in obesity care.

This class is not one-size-fits-all. Dose titration, tolerability, and treatment goals differ across patients. The same molecule may be used for diabetes indications, obesity indications, or both, depending on product labeling.

You may also hear about tirzepatide in GLP-1 discussions. It targets both GIP and GLP-1 receptors, so it is related but mechanistically distinct from single-pathway GLP-1 receptor agonists.

Sources: [1] [2] [3] [7] [8]

Medication comparison checklist (quick table)

Use this section like a starter table: molecule, brand, route/frequency, and FDA-labeled use. Then confirm exact eligibility and contraindications with your clinician and the current prescribing information.

• Semaglutide products (Ozempic, Wegovy, Rybelsus): weekly injection or daily oral formulation depending on product; indications differ by label.
• Liraglutide products (Victoza, Saxenda, and FDA-approved generic liraglutide): daily injection; indications differ by product and population.
• Other GLP-1 receptor agonists used in type 2 diabetes include dulaglutide, exenatide, and lixisenatide products.
• Dual GIP/GLP-1 products (Mounjaro, Zepbound): commonly grouped in patient research with GLP-1 options but are not single-pathway GLP-1 agonists.
• Checklist before comparing options: approved indication, route/frequency, titration schedule, common adverse effects, and cardiovascular-label language when applicable.

Sources: [1] [2] [3] [4] [5] [7] [8]

Patient questions to bring to your first GLP-1 conversation

First-time users usually do better with a written list of questions instead of trying to remember details later. Ask for a clear follow-up plan that includes dose changes, symptom thresholds, and check-in timing.

• What is the exact treatment goal for me right now: glycemic control, weight management, cardiovascular risk reduction, or a combination?
• What titration schedule should I expect, and what symptoms should trigger a call instead of waiting for the next visit?
• How should I handle missed doses, travel, and refrigeration/storage logistics?
• Which adverse effects are common and self-limited versus urgent warning signs that need same-day care?
• How will we measure success at 1 month, 3 months, and beyond if side effects or supply issues occur?

Sources: [1] [2] [3] [6]

Safety and authenticity checks before paying or injecting

If you are offered a product described as semaglutide or tirzepatide from a non-standard source, verify that it is FDA-approved for your use case and dispensed by a state-licensed pharmacy. FDA has repeatedly warned about quality and safety risks with unapproved or fraudulent products, including compounded products with dosing errors and counterfeit versions.

This does not mean every compounded product is automatically unsafe, but it does mean first-time researchers should understand the difference between FDA-approved drugs and unapproved versions that are not reviewed for safety, effectiveness, and quality in the same way.

Sources: [5] [6]

Bottom line

A good first step is to treat GLP-1 research as a structured comparison problem: mechanism, approved indication, dosing reality, and safety checks.

Bring a shortlist and a question checklist to your clinician so the decision is based on your goals and risk profile, not social media momentum.

Sources: [1] [2] [6]